迪安诊断
(300244)
| 流通市值：82.34亿 | | | 总市值：102.62亿 |
| 流通股本：5.01亿 | | | 总股本：6.25亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,565,586,728.42 | 4,936,484,994.33 | 2,365,125,686.41 | 12,196,223,734.01 |
| 营业收入 | 7,565,586,728.42 | 4,936,484,994.33 | 2,365,125,686.41 | 12,196,223,734.01 |
| 二、营业总成本 | 7,011,768,898.52 | 4,643,502,517.31 | 2,246,966,921.12 | 11,403,545,691.66 |
| 营业成本 | 5,366,020,438.92 | 3,574,366,089.38 | 1,740,876,331.02 | 8,779,606,550.03 |
| 税金及附加 | 31,024,282.69 | 19,542,576.9 | 10,168,333.59 | 43,325,165.81 |
| 销售费用 | 830,833,984.8 | 534,126,852.74 | 258,905,714.22 | 1,217,768,951.79 |
| 管理费用 | 518,131,891.35 | 329,307,750.23 | 136,784,132.2 | 858,931,870.6 |
| 研发费用 | 169,463,374.03 | 116,121,837.11 | 57,443,584.55 | 305,880,933.28 |
| 财务费用 | 96,294,926.73 | 70,037,410.95 | 42,788,825.54 | 198,032,220.15 |
| 其中:利息费用 | 108,922,186.26 | 76,731,696.59 | 42,786,490.45 | 203,027,893.07 |
| 其中:利息收入 | 23,153,384.53 | 12,421,807.74 | 3,941,698.06 | 25,668,594.64 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 11,493,333.82 | 7,353,507.97 | 2,565,031.54 | -12,696,720.83 |
| 加:投资收益 | 13,340,411.44 | 10,703,242.12 | -6,532,709.05 | 38,712,506.27 |
| 资产处置收益 | -631,731.09 | 1,181,965.86 | -774,268.67 | -1,476,191.11 |
| 资产减值损失(新) | 720,414.73 | -169,884.86 | -1,414,134.43 | -401,578,630 |
| 信用减值损失(新) | -317,477,767.23 | -215,301,292.37 | -100,237,182.78 | -483,449,219.1 |
| 其他收益 | 23,767,240.13 | 19,102,935.98 | 11,657,758.55 | 36,695,034.82 |
| 四、营业利润 | 285,029,731.7 | 115,852,951.72 | 23,423,260.45 | -31,115,177.6 |
| 加:营业外收入 | 3,708,717.82 | 3,092,202.94 | 263,034.82 | 11,348,915.49 |
| 减:营业外支出 | 12,649,316.3 | 8,145,477.49 | 2,972,696.75 | 32,059,988.7 |
| 五、利润总额 | 276,089,133.22 | 110,799,677.17 | 20,713,598.52 | -51,826,250.81 |
| 减:所得税费用 | 94,078,295.92 | 28,596,901.51 | 16,541,322.46 | 117,406,845.49 |
| 六、净利润 | 182,010,837.3 | 82,202,775.66 | 4,172,276.06 | -169,233,096.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 182,010,837.3 | 82,202,775.66 | 4,172,276.06 | -169,233,096.3 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 56,704,839.25 | 10,277,234.44 | -21,005,565.65 | -357,277,652.58 |
| 少数股东损益 | 125,305,998.05 | 71,925,541.22 | 25,177,841.71 | 188,044,556.28 |
| 扣除非经常损益后的净利润 | 35,551,854.51 | -9,235,485.89 | -26,305,778.11 | -380,108,163.92 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.02 | -0.03 | -0.58 |
| (二)稀释每股收益 | 0.09 | 0.02 | -0.03 | -0.58 |
| 八、其他综合收益 | - | - | - | 20,871.95 |
| 归属于母公司股东的其他综合收益 | - | - | - | 20,871.95 |
| 九、综合收益总额 | 182,010,837.3 | 82,202,775.66 | 4,172,276.06 | -169,212,224.35 |
| 归属于母公司股东的综合收益总额 | 56,704,839.25 | 10,277,234.44 | -21,005,565.65 | -357,256,780.63 |
| 归属于少数股东的综合收益总额 | 125,305,998.05 | 71,925,541.22 | 25,177,841.71 | 188,044,556.28 |
| 公告日期 | 2025-10-24 | 2025-08-21 | 2025-04-29 | 2025-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |